CIETAI and Sequential Radiotherapy in Squamous Lung Cancer
Status:
Not yet recruiting
Trial end date:
2026-06-01
Target enrollment:
Participant gender:
Summary
Central-type lung cancer refers to lung malignancies originating from the segmental bronchi
and above. The most common tissue type is squamous cell carcinoma. Patients often present
with cough, hemoptysis, hoarseness and also some critical conditions including superior vena
caval obstruction syndrome. Therefore, effective treatment should be implemented as early as
possible to rapidly reduce tumor burden and control the progression of the disease. Most of
the central-type NSCLC are classified into T3-4, N1-2 stage and are non-resectable. The
PACIFIC study changed the standard treatment model for inoperable locally advanced lung
cancer with synchronous chemoradiotherapy and sequential PD-L1 immunotherapy. In clinical
practice, Chinese patients often failed to finish concurrent chemoradiotherapy for high
toxicity. In addition, combination with PD-1/PD-L1 inhibitors increased the risk of immune
related pneumonia.
Bronchial artery infusion (BAI), that directly infused drugs (chemo and PD-1 inhibitor)
through tumor-nourishing arteries, has potential advantages in the treatment of central-type
lung cancer. The drug concentration in tumor region increased to potentiate the antitumoral
effect and also reduced the systemic adverse reactions.
In this study, bronchial artery interventional therapy is conducted with precedence. The
protocol for bronchial artery intervention includes infusion of chemo and PD-1 inhibitor
followed by bronchial artery embolism (Chemo-Immulo-embolization via Tumor arterial, CIETAI).
Followed CIETAI, two cycles of chemo/PD-1 therapy are planned to carried out before
radiotherapy. After radiotherapy, maintenance PD-1 inhibitor are initiated for 1 year or
until progression.